The ASTRAL trial, the largest randomized trial of ... Magnetic resonance; RAS: Renal artery stenosis. BNP: B-type natriuretic peptide; BP: Blood pressure; EDV: End diastolic volume; FFR ...

ASTRAL No difference Only two-thirds of trial participants had severe stenosis ... and STAR Stent Placement in Patients With Atherosclerotic Renal Artery Stenosis and Impaired Renal Function. Given ...

Renal artery stenosis and all-cause 30-day death rates were 0% ... that should be investigated in future trials.

The ASTRAL trial (Angioplasty and Stenting for Renal Artery Lesions) recruited 806 patients between 2000 and 2007. Patients with atherosclerotic renal artery stenosis (RAS) and clinician uncertainty ...

In both trials, reduction in ischaemic events come with a ... of progression of renal dysfunction caused by atherosclerotic ostial stenosis of the renal artery), ASTRAL (angioplasty and stenting for ...

Verve Medical, Inc. (Verve) announced today that the Company has received approval from the US Food & Drug Administration (FDA) to initiate its Natural Orifice via renal pelvis denervation (NOVEL- ...

1–4 Although occlusion of SVG is regarded as a complex process, platelet activation and thrombosis likely contribute to early process of SVG stenosis or occlusion. The Timing of Platelet Inhibition ...

Drug adherence assessed by urine testing was similarly high in both trial arms (about 90% at 6 months). In terms of safety, there were no deaths and no cases of severe renal dysfunction in either ...

More than 90% of the time, renal artery stenosis is caused by atherosclerosis, a process in which plaque made up of fats, cholesterol, and other materials builds up on the walls of the blood ...

or new renal artery stenosis of more than 70% within 6 months. The trial is registered with ClinicalTrials.gov, NCT01418261. From Sep 29, 2011, to May 6, 2013, 1442 patients were screened, of whom 535 ...